Search Protocols under revision. Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsProtocol groupDermatologic OncologyT-Cell and NK-Cell NeoplasmsDiseaseNHL, T-Cell Type, cutaneous, Mycosis fungoidesNHL, T-Cell Type, Cutaneous, UnspecifiedNHL, T-Cell Type, Cutaneous Primary, CD30-PositiveNHL, T-Cell Type, Sézary SyndromeSubgroupCD30+ICD10C84.0C84.1C84.8C86.6MeSHLymphoma, T-Cell, CutaneousMycosis FungoidesSezary SyndromeSequenceMAVORIC: MOGA1, CTCL, C1 (PID1397) -|- C2-12 (PID1398)ChemotherapyChemo-substanceBexaroteneBrentuximab vedotinCladribineDenileukin DiftitoxDoxorubicin pegylated liposomalGemcitabineMogamulizumabChemo-substanceBexaroteneBrentuximab vedotinCladribineDenileukin DiftitoxDoxorubicin pegylated liposomalGemcitabineMogamulizumabChemo-substanceBexaroteneBrentuximab vedotinCladribineDenileukin DiftitoxDoxorubicin pegylated liposomalGemcitabineMogamulizumabChemo-substanceBexaroteneBrentuximab vedotinCladribineDenileukin DiftitoxDoxorubicin pegylated liposomalGemcitabineMogamulizumabNo. Substances1 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPyridoxineSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPyridoxineSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPyridoxineSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPyridoxineNo. Substances234Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationRelapse therapySecond lineseveral possibleThird line Therapy phaseTherapy intentiondisease controlpalliativeRisksAnemia Hb below 8g/dlAnemia Hb below 10g/dlAstheniaCapillary Leak SyndromeDiarrheaEdemaEmetogenicityEmetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHand-Foot SyndromeHeadacheHypertensionHypoalbuminemiaIncrease AminotransferasesInfectionsInfusion ReactionLeukopeniaMucositisNauseaNeuropathyNeutropeniaPneumoniaPruritusPyrexiaSepsisThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorDuvic MFoss FMKim YHPrince HMQuereux GSaven ADiseasefortgeschrittenes, kutanes T-Zell-LymphomKutanes T-Zell-Lymphom (inkl. Mycosis fungoides oder Sézary-Syndrom)kutanes T-Zell-Lymphom, CD30+, mindestens eine Vortherapie, ECOG 0-2Refraktäres kutanes T-Zell-Lymphom, eine oder mehr Vorbehandlungen, Stadium I-IIARefraktäres oder rezidivierendes kutanes T-Zell-Lymphom (Mycosis fungoides oder Sézary-Syndrom), Stadium IA bis IVA, ECOG 0-1refraktäres oder rezidivierendes kutanes T-Zell-Lymphom, 2 oder mehr Vorbehandlungen, ECOG 0-2refraktäres oder rezidivierendes kutanes T-Zell-Lymphom, eine oder mehr Vorbehandlungen, ECOG 0-1OriginDepartment of Dermatology, The University of Texas M. D. Anderson Cancer Center, HoustonDepartments of Dermatology, Centre Hospitalier Universitaire, Nantes, FranceDepartments of Dermatology, M. D. Anderson Cancer Center, Houston, TexasDivision of Cancer Medicine, Peter MacCallum Cancer Centre, The University of Melbourne, ALCANZADivision of Hematology and Oncology, Scripps Clinic, La Jolla, CAStanford University, Stanford, CA, USA, MAVORICYale University School of Medicine, New Haven, CTProtocols in Revision 8 protocols foundBexarotene 300, cutaneous T-cell Lymphoma (PID3109 V1.0)Brentuximab Vedotin 1.8, cutaneous T-cell lymphoma (PID1389 V1.0)Cladribine 0.05, cutaneous T-cell Lymphoma (PID3053 V1.0)Denileukin Diftitox 9, cutaneous T-cell Lymphoma (PID3046 V1.0)Gemcitabine 1000, cutaneous T-cell lymphoma (PID1388 V1.0)Mogamulizumab 1, cutaneous T-cell lymphoma, cycle 1 (PID1397 V1.0)Mogamulizumab 1, cutaneous T-cell lymphoma, cycle 2-12 (PID1398 V1.0)Pegylated Doxorubicin Liposomal 40, cutaneous T-cell lymphoma (PID1387 V1.0)
